Scotiabank analyst Greg Harrison lowered the firm’s price target on Vera Therapeutics (VERA) to $55 from $60 and keeps an Outperform rating on the shares. The firm is updating its price targets ...

An Akron Public Schools board member said he plans to make a motion at Monday's board meeting to have the superintendent put on administrative leave. The Rev. Greg Harrison said Tuesday that ...

Scotiabank analyst Greg Harrison lowered the firm’s price target on Travere Therapeutics (TVTX) to $30 from $32 and keeps an Outperform rating on the shares. The company recently presented ...

Scotiabank analyst Greg Harrison maintained a Buy rating on Beam Therapeutics (BEAM – Research Report) today and set a price target of $40.00. The company’s shares closed last Friday at $15.27.

The Rev. Greg Harrison said Tuesday that following the Beacon Journal's release of a six-month investigation into allegations against Superintendent Michael Robinson by current and former staff ...